Latest Breaking News On - வழிகாட்டி சிகிச்சை - Page 1 : comparemela.com

List: 11 Biotechs to Know Leading Gene Editing

List: 11 Biotechs to Know Leading Gene Editing
businessinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businessinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomApellis pharmaceuticalsGuide therapeuticsWhile sangamoPrime medicineFlagship pioneeringஒன்றுபட்டது மாநிலங்களில்ஒன்றுபட்டது கிஂக்டம்சாப்ட் பேங்க்வழிகாட்டி சிகிச்சைப்ரைம் மருந்து

Apellis taps Beam s base-editing tech to broaden autoimmune disease scope

Apellis taps Beam’s base-editing tech to broaden autoimmune disease scope Apellis taps Beam’s base-editing tech to broaden autoimmune disease scope Fresh off its first FDA approval, Apellis Pharmaceuticals is teaming up with Beam Therapeutics, a partnership that will use Beam’s base-editing technology to develop new therapies for complement system disorders. Apellis has committed to pay Beam $75 million to kick off the alliance. Shares0 Apellis Pharmaceuticals recently won its first FDA approval for a drug that treats a rare blood disorder by hitting a specific target in the complement system, a family of proteins that helps cells of the immune system. The company wants to bring complement system drugs to other diseases in other parts of the body and it is turning to the gene-editing technology of Beam Therapeutics for help.

United kingdomUnited statesJohn evansApellis pharmaceuticalsBeam therapeuticsMassachusetts based apellisGuide therapeuticsஒன்றுபட்டது கிஂக்டம்ஒன்றுபட்டது மாநிலங்களில்ஜான் எவன்ஸ்உத்திரம் சிகிச்சைவழிகாட்டி சிகிச்சை

Biogen looks to build better gene therapies through latest deal

Dive Brief: In its latest investment into the field of gene therapy, Biogen has licensed technology that it believes could help create new treatments for central nervous system and neuromuscular disorders. The deal with Capsigen, a Washington-based biotech, has Biogen paying $15 million at the start and potentially up to $1.3 billion later on, provided certain research, development and sales milestones are hit. Capsigen is also eligible for royalties on future net sales on any resulting products that use its technology. Capsigen specializes in developing adeno-associated virus vectors, which are used like microscopic shuttles to deliver genetic medicine into human cells. The deal with Biogen tasks Capsigen with creating new capsids the outer coating which protects the genetic payload that are customized to target specific diseases.

North carolinaUnited statesAl sandrockAndreessen horowitzDrug administrationDive briefNightstar therapeuticsSangamo therapeuticsDyno therapeuticsBeam therapeuticsGuide therapeuticsவடக்கு கரோலினாஒன்றுபட்டது மாநிலங்களில்அல் சாண்ட்ராக்அன்றீஸ்ஸென் ஹொரோவிட்ஸ்டைவ் சுருக்கமான

Beam Inc (NYSE:BEAM) - Beam Therapeutics Adds To Drug Delivery With $120M GuideTx Buy

Beam Inc (NYSE:BEAM) - Beam Therapeutics Adds To Drug Delivery With $120M GuideTx Buy
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

Beam therapeutics incGuide therapeuticsஉத்திரம் சிகிச்சை இன்க்வழிகாட்டி சிகிச்சை

Beam, capitalizing on stock surge, buys gene therapy tools developer for $120M

Dive Brief: High-profile gene editing startup Beam Therapeutics has acquired Guide Therapeutics, a developer of tools used to deliver genetic medicines into cells, in a $120 million all-stock deal that capitalizes on the recent run-up of Beam s share price. The acquisition, which Beam completed on Tuesday, centers on technology Guide has developed to more efficiently shuttle gene editing therapies to target tissues inside the body. Guide investors could receive as much as $320 million more in Beam stock should its technology succeed and hit certain unspecified milestones. Launched in May 2018, Beam is working on more precise forms of gene editing developed by Harvard University s David Liu and by Feng Zhang, a CRISPR pioneer and member of the Broad Institute of MIT and Harvard. Shares in the company have soared since October, boosting its valuation to more than $5 billion.

United statesGiuseppe ciaramellaFeng zhangBroad instituteHarvard university david liuDrug administrationDive briefBeam therapeuticsGuide therapeuticsHarvard universityDavid liuGeorgia techGene therapyஒன்றுபட்டது மாநிலங்களில்ஃபெங் ஜாங்பரந்த நிறுவனம்